Administration of BMS-986368

Phase 2

Bristol-Myers Squibb Company (BMY)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jun '27

BMYPhase 2$126.6B

Administration of BMS-986368 Phase 2 Est. Readout (STIPS)

Administration of BMS-986368• Post-Stroke Spasticity42

Jun 2027~Estimated

CT.gov

00%

Competitive Landscape

0 competitors in Post-Stroke Spasticity

View Full Landscape

Drug Information

Target Indication

Post-Stroke Spasticity

Clinical Trial

NCT07704840

Last updated: 10/27/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

BMY

Bristol-Myers Squibb Company

Pharmaceutical Preparations•North America•NYSE

Related Pipeline

Topical DapsonePhase 3

Cetuximab-induced Papulopustular (Acneiform) Rash Who Have

Tegafur-gimeracil-oteracil potassiumPhase 3

Gastric Cancer

oral antibioticsPhase 3

Cetuximab-induced Papulopustular (Acneiform) Rash Who Have

Anti-Tumor Necrosing Factor (TNF) TherapyPhase 3

Rheumatoid Arthritis

Irbesartan/HCTZPhase 3

Hypertension

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts